Cardiac action potential simulation references

2026 - T-World Virtual Human Cardiomyocyte. I. Development, Validation, and Cell Arrhythmogenesis.. Tomek J et al

2024 - Computational modeling of cardiac electrophysiology and arrhythmogenesis: toward clinical translation. Trayanova NA et al

2024 - Computational Modeling of Cardiac Electrophysiology. Ni H & Grandi E

2022 - Computational cardiac safety testing. Mirams GR

2022 - A Novel In Silico Electromechanical Model of Human Ventricular Cardiomyocyte. Bartolucci C et al

2021 - Evolution of mathematical models of cardiomyocyte electrophysiology. Amuzescu B et al

2020 - In Silico Classifiers for the Assessment of Drug Proarrhythmicity. Llopis-Lorente J et al

2020 - In silico models for evaluating proarrhythmic risk of drugs. Hwang M et al

2020 - General Principles for the Validation of Proarrhythmia Risk Prediction Models: An Extension of the CiPA In Silico Strategy. Li Z et al

2019 - Development, calibration and validation of a novel human ventricular myocyte model in health, disease and drug block. Tomek J et al

2017 - Am I or am I not proarrhythmic ? Comparison of various classifications of drug TdP propensity. Winisowka B & Polak S

2016 - Evolution of strategies to improve preclinical cardiac safety testing. Gintant G et al

2013 - Simulation of early after depolarisation in non failing-human ventricular myocytes: can this help cardiac safety pharmacology. Christophe B

2011 - Simulation of the undiseased human cardiac ventricular action potential: model formulation and experimental validation. O'Hara T et al

2011 - Is it time for in silico simulation of drug cardiac side effects? Mirams GR  & Noble